scholarly journals Targeting intracellular protein–protein interactions with macrocyclic peptides

Author(s):  
Marina Buyanova ◽  
Dehua Pei
2021 ◽  
Author(s):  
Shuhui Lim ◽  
Nicolas Boyer ◽  
Nicole Boo ◽  
Chunhui Huang ◽  
Gireedhar Venkatachalam ◽  
...  

Macrocyclic peptides have the potential to address intracellular protein-protein interactions (PPIs) of high value therapeutic targets that have proven largely intractable to small molecules. Here, we report broadly applicable lessons...


2021 ◽  
Vol 29 ◽  
pp. 115906
Author(s):  
Sanjeevini Babu Reddiar ◽  
Hareth Al-Wassiti ◽  
Colin W. Pouton ◽  
Cameron J. Nowell ◽  
Macgregor A. Matthews ◽  
...  

2020 ◽  
Vol 142 (47) ◽  
pp. 19950-19955
Author(s):  
Stephen E. Miller ◽  
Kohei Tsuji ◽  
Rachel P.M. Abrams ◽  
Terrence R. Burke ◽  
Joel P. Schneider

2017 ◽  
Vol 60 (21) ◽  
pp. 8982-8988 ◽  
Author(s):  
Dennis M. Krüger ◽  
Adrian Glas ◽  
David Bier ◽  
Nicole Pospiech ◽  
Kerstin Wallraven ◽  
...  

2016 ◽  
Vol 128 (36) ◽  
pp. 10770-10773 ◽  
Author(s):  
Daisuke Fujiwara ◽  
Hidekazu Kitada ◽  
Masahiro Oguri ◽  
Toshio Nishihara ◽  
Masataka Michigami ◽  
...  

2021 ◽  
Vol 75 (6) ◽  
pp. 522-524
Author(s):  
Thomas E. Vorherr

This review on intracellular delivery and oral bioavailability of peptides reflects a number of principal investigations at Novartis. Our studies were aimed at either understanding features enabling peptides to interfere with intracellular protein–protein interactions, or to achieve a more patient-friendly delivery by the oral route. In the light of these objectives, we have also spent some effort on assay development to come up with alternative methods for monitoring cellular peptide uptake. This summary of our insights is intended to help in the assessment and development of peptide therapeutics requiring membrane transition


Sign in / Sign up

Export Citation Format

Share Document